Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Kohei Kaku MD, PhD

Kohei Kaku MD, PhD

Research Professor, Department of Internal Medicine, Kawasaki Medical School, JAPAN; Research Professor, Kawasaki University of Medical Welfare, JAPAN
Research Professor, Department of Internal Medicine, Kawasaki Medical School, JAPAN; Research Professor, Kawasaki University of Medical Welfare, JAPAN

Disclosures

Dr. Kaku reports the follow disclosures:
  • Advisory role: Astelas Pharma, Sanwa Kagaku Kenkyusho, Novo Nordisk Pharma, Mitsubishi Tanabe Pharma, Sumitomo Dainippon Pharma, Takeda Pharmaceutical
  • Honoraria: Astelas Pharma, AstraZeneca, MSD, Kowa, Novo Nordisk Pharma, Mitsubishi Tanabe Pharma, Boehringer Ingelheim, Ono Pharmaceutical, Taisho Toyama Pharmaceutical, Takeda Pharmaceutical
  • Research Grant: Boehringer Ingelheim, Mitsubishi Tanabe Pharma

Recent Contributions to PracticeUpdate:

  1. Clinical Markers of Insulin Resistance Are Associated With Altered Glycemic Response to DPP-4 Inhibitors

Most Read This Week

Recently Updated